Leerink Partners Initiates Coverage On X4 Pharmaceuticals with Outperform Rating, Announces Price Target of $12
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Leerink Partners analyst Thomas Smith initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Outperform rating and announces Price Target of $12.
Leerink Partners analyst Thomas Smith initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a Outperform rating and announces Price Target of $12.